Short answer
Oncology Institute, Inc. (TOI) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Updated investor presentation supersedes the prior Exhibit 99.1 presentation.
Oncology Institute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Updated investor presentation supersedes the prior Exhibit 99.1 presentation
- Revised materials intended for investor meetings, potentially updating Starling Oncology’s strategic and financial messaging
- Investors should review Exhibit 99.1 for the substantive changes
Item EX-99.1 · Exhibit EX-99.1
- Investor presentation highlights Starling’s oncology value-based-care platform, combining capitated care, fee-for-service, specialty pharmacy, and clinical services
- FY2026 revenue guidance $650M-$660M, with Adjusted EBITDA guidance $4M-$6M and free cash flow guidance $5M-$10M
- 3Q26 revenue $170M, up 24% YoY, with Adjusted EBITDA $3.4M versus $(3.5)M in 3Q25
- Specialty pharmacy revenue $109M, up 44% YoY, with 24% gross margin
- Medical loss ratio 81%, down 400 basis points sequentially, supporting improving economics in delegated contracts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oncology Institute, Inc. 8-K filings
Get the next TOI 8-K as it lands
Follow TOI for push alerts, or ask the research agent what this filing means.